Lilly’s £630M Investment in Novartis’ Failed Pain Target.
In the highly competitive world of pharmaceuticals, companies are constantly looking for the next big breakthrough drug. The quest for new treatments can be a risky and expensive endeavour, with no guarantee of success. Eli Lilly’s recent investment of $630 million in a failed pain target from Novartis is a prime example of the high-stakes […]